Insider Transactions in Q4 2023 at Acadia Pharmaceuticals Inc (ACAD)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 15
2023
|
James Kihara PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
2,000
-15.36%
|
$56,000
$28.3 P/Share
|
|
Nov 24
2023
|
Elizabeth A. Garofalo |
SELL
Bona fide gift
|
Direct |
2,918
-15.54%
|
-
|
|
Nov 20
2023
|
James Kihara PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,985
-13.22%
|
$43,670
$22.64 P/Share
|
|
Nov 20
2023
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,108
-19.96%
|
$112,376
$22.64 P/Share
|
|
Nov 20
2023
|
Brendan Teehan EVP, COO, HEAD OF COMMERCIAL |
SELL
Open market or private sale
|
Direct |
4,960
-14.03%
|
$109,120
$22.64 P/Share
|
|
Nov 17
2023
|
James Kihara PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,964
+12.43%
|
-
|
|
Nov 17
2023
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,912
+17.79%
|
-
|
|
Nov 17
2023
|
Brendan Teehan EVP, COO, HEAD OF COMMERCIAL |
BUY
Exercise of conversion of derivative security
|
Direct |
9,912
+13.16%
|
-
|
|
Oct 12
2023
|
Adora Ndu |
BUY
Exercise of conversion of derivative security
|
Direct |
4,381
+50.0%
|
-
|
|
Oct 06
2023
|
Austin D. Kim EVP,General Counsel, Secretary |
SELL
Open market or private sale
|
Direct |
16,369
-26.31%
|
$343,749
$21.96 P/Share
|
|
Oct 06
2023
|
Stephen Davis CEO |
SELL
Open market or private sale
|
Direct |
51,563
-36.65%
|
$1,082,823
$21.96 P/Share
|
|
Oct 05
2023
|
Austin D. Kim EVP,General Counsel, Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
36,174
+36.76%
|
-
|
|
Oct 05
2023
|
Stephen Davis CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
103,999
+42.5%
|
-
|